title: Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
abstract: The racemic compound carvedilol is a multiple-action oral antihypertensive drug that exhibits both vasodilator and non-selective beta-adrenergic blocking activities. The effects of the levorotatory S-enantiomer [S(-)-CARV] are vasodilatation and beta-blockade. The R(+)-enantiomer [R(+)-CARV] is a pure vasodilating agent. Quantitative determination of the enantiomers in human plasma by HPLC was carried out after formation of diastereoisomers with the chiral reagent 2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl isothiocyanate (GITC). The pharmacokinetics of the enantiomers were studied following i.v. (12.5 mg in 1 h) and p.o. (50 mg) administration of racemic carvedilol in ten healthy male subjects according to a randomized crossover design. The AUCs of S(-)-CARV were significantly lower than those of R(+)-CARV after both i.v. and p.o. administration. The systemic clearance of the two enantiomers was significantly different, whereas half-lives and apparent distribution volumes were comparable. Following p.o. administration, the absolute bioavailability (31.1% and 15.1%, respectively) and maximal plasma concentrations of R(+)-CARV were twice those of S(-)-CARV. A similar difference was found in the half-lives. A close correlation existed between enantiomeric ratios after i.v. and after p.o. administration, demonstrating slight intraindividual variability. The preferential systemic clearance of the S(-)-enantiomer suggests stereoselective hepatic metabolism of carvedilol, becoming especially apparent after p.o. administration. The small intrasubject variability in enantiomer ratios indicates a relatively constant relation of beta-blockade to vasodilation during chronic treatment.
authors.affiliation: Boehringer Mannheim GmbH, Federal Republic of Germany.
authors.forename: G
authors.initials: G
authors.lastname: Neugebauer
authors.forename: W
authors.initials: W
authors.lastname: Akpan
authors.forename: B
authors.initials: B
authors.lastname: Kaufmann
authors.forename: K
authors.initials: K
authors.lastname: Reiff
mesh_terms: D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000328:Adult; D001682:Biological Availability; D002227:Carbazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000077261:Carvedilol; D002851:Chromatography, High Pressure Liquid; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D017879:Isothiocyanates; D008297:Male; D011412:Propanolamines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013237:Stereoisomerism; D013861:Thiocyanates / Q000378:metabolism
chemical_list: D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D017879:Isothiocyanates; D011412:Propanolamines; D013861:Thiocyanates; D000077261:Carvedilol; C041943:2,3,4,6-tetra-O-acetylglucopyranosylisothiocyanate